Oncternal Therapeutics Inc (ONCT)
$7.09
+0.23
(+3.35%)▲
Performance
- $7.09$7.09$7.09
0.0%
Downside
Day's Volatility :0.0%
Upside
0.0%
- $5.57$13.14$7.09
21.44%
Downside
52 Weeks Volatility :57.61%
Upside
46.04%
Returns
| Period | Oncternal Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -17.25% | 6.5% | 0.0% |
6 Months | -23.95% | 7.1% | 0.0% |
1 Year | -14.25% | 9.8% | 0.0% |
3 Years | -91.32% | 14.2% | -20.2% |
Highlights
Market Capitalization | 20.9M |
Book Value | $7.75 |
Earnings Per Share (EPS) | -12.33 |
Wall Street Target Price | 27.67 |
Profit Margin | 0.0% |
Operating Margin TTM | -1542.88% |
Return On Assets TTM | -54.83% |
Return On Equity TTM | -96.48% |
Revenue TTM | 1.2M |
Revenue Per Share TTM | 0.39 |
Quarterly Revenue Growth YOY | 180.29999999999998% |
Gross Profit TTM | -31.5M |
Diluted Eps TTM | -12.33 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -11.77 |
EPS Estimate Next Year | -9.42 |
EPS Estimate Current Quarter | -2.88 |
EPS Estimate Next Quarter | -2.6 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 290.27%
Technicals Summary
Sell
Neutral
Buy
Oncternal Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Oncternal Therapeutics Inc | -10.91% | -23.95% | -14.25% | -91.32% | -93.13% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Oncternal Therapeutics Inc | NA | NA | NA | -11.77 | -0.96 | -0.55 | NA | 7.75 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Oncternal Therapeutics Inc | Buy | $20.9M | -93.13% | NA | 0.0% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Oncternal Therapeutics Inc
Increasing Revenue
Revenue is up for the last 4 quarters, 106.0K → 569.0K (in $), with an average increase of 42.8% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -9.86M → -8.38M (in $), with an average increase of 8.4% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 75.8%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 277.8%
Institutional Holdings
Vanguard Group Inc
4.83%Millennium Management LLC
3.48%BlackRock Inc
1.33%Dimensional Fund Advisors, Inc.
0.87%Richmond Brothers Inc
0.83%Geode Capital Management, LLC
0.81%
Company Information
oncternal therapeutics, inc., a clinical-stage biopharmaceutical company, develops oncology therapies for the treatment of cancers with critical unmet medical need. the company's product pipeline include cirmtuzumab, a monoclonal antibody designed to inhibit the receptor-tyrosine kinase-like orphan receptor 1 (ror1) that is in phase i/ii clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia; and is in phase ib clinical trial in combination with paclitaxel for the treatment of women with human epidermal growth factor receptor 2-negative metastatic or breast cancer. it also develops tk-216, a small-molecule that is designed to inhibit e26 transformation specific family of oncoproteins, which is in phase i clinical trial to treat patients with ewing sarcoma and in combination with vincristine chemotherapy. in addition, the company develops a chimeric antigen receptor-t product candidate that targets ror1, whic
Organization | Oncternal Therapeutics Inc |
Employees | 27 |
CEO | Dr. James B. Breitmeyer M.D., Ph.D. |
Industry | Biotechnology |
Discover More
A Spac I Acquisition Corp
$7.09
+3.35%
Keyarch Acquisition Corp
$7.09
+3.35%
Connexa Sports Technologies Inc
$7.09
+3.35%
Us Value Etf
$7.09
+3.35%
First Wave Biopharma Inc
$7.09
+3.35%
Global X Msci Next Emerging
$7.09
+3.35%
Fat Projects Acquisition Corp
$7.09
+3.35%
Capital Link Global Fintech
$7.09
+3.35%
Applied Uv Inc
$7.09
+3.35%